E/C/F/TAF

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

252 competitors in Hepatitis B

#DrugCompanyPhaseTrials

1

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

22

Measles Vaccine

GSK

Phase 3

13

Hepatitis B Adjuvanted Vaccine

GSK

Phase 3

44

Hexaxim

Sanofi

Phase 3

15

Vemlidy

Gilead

Preclinical

86

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

157

E/C/F/TAF

Gilead

Phase 3

18

Henogen HB Vaccine

HHenogen

Phase 3

19

Nulojix

Bristol-Myers Squibb

Preclinical

110

HEPCLUDEX

Gilead

Preclinical

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Antiretroviral Treatment6 trials

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

Completed·Gilead·Phase 2/3·NCT01854775·129 enrolled

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Completed·Gilead·Phase 3·NCT01705574·583 enrolled

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 3·NCT01780506·872 enrolled

Show 3 more trials

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 3·NCT01797445·872 enrolled

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Completed·Gilead·Phase 3·NCT01967940·55 enrolled

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 2·NCT01497899·279 enrolled

Treatment2 trials

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Completed·Gilead·Phase 3·NCT02707601·150 enrolled

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Completed·Gilead·Phase 3·NCT01968551·158 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Completed·Gilead·Phase 3·NCT02652624·472 enrolled

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Completed·Gilead·Phase 3·NCT02605954·275 enrolled

Itching1 trial

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Completed·Gilead·Phase 3·NCT01815736·1,443 enrolled

Hepatitis B1 trial

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

Completed·Gilead·Phase 3·NCT02071082·79 enrolled

8 more indications

Efficacy and Safety1 trial

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

Completed·Gilead·Phase 2/3·NCT02276612·60 enrolled

Tenofovir Disoproxil Fumarate1 trial

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Completed·Gilead·Phase 3·NCT02616783·167 enrolled

Renal Impairment1 trial

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Completed·Gilead·Phase 3·NCT01818596·252 enrolled

Insulin Sensitivity1 trial

Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication

Completed·TTechnical University of Munich·Phase 1·NCT03092206·30 enrolled

Adolescent1 trial

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Recruiting·Gilead·Phase 4·NCT06337032·350 enrolled

Resistance1 trial

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

Completed·Gilead·Phase 3·NCT02616029·66 enrolled

Hemodialysis1 trial

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Completed·Gilead·Phase 3·NCT02600819·55 enrolled

Infection1 trial

HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection

Completed·OOttawa Hospital Research Institute·Phase 3·NCT02660905·25 enrolled

Details

Drug Info

Related News